Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$1.4 - $3.24 $29,493 - $68,257
21,067 New
21,067 $64,000
Q1 2023

May 15, 2023

SELL
$4.81 - $8.88 $2,433 - $4,493
-506 Reduced 13.23%
3,318 $20,000
Q4 2022

Feb 14, 2023

BUY
$6.52 - $8.05 $24,932 - $30,783
3,824 New
3,824 $0

Others Institutions Holding KOD

About Kodiak Sciences Inc.


  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $455M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Point72 Middle East Fze Portfolio

Follow Point72 Middle East Fze and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Middle East Fze, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Middle East Fze with notifications on news.